Fidelity Investments
MRTX

Fidelity Investments’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Fidelity Investments’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4,240
Closed -$249K – 5835
2023
Q4 		$249K Sell
4,240
-1,523,588
-100% -$85.7M ﹤0.01% 2895
2023
Q3 		$66.6M Buy
1,527,828
+1,404,045
+1,134% +$50.1M 0.01% 1141
2023
Q2 		$4.47M Sell
123,783
-54,300
-30% -$2.24M ﹤0.01% 2097
2023
Q1 		$6.62M Sell
178,083
-507,945
-74% -$22.8M ﹤0.01% 2015
2022
Q4 		$31.1M Sell
686,028
-1,454,594
-68% -$94.1M ﹤0.01% 1450
2022
Q3 		$150M Buy
2,140,622
+133,158
+7% +$9.85M 0.02% 789
2022
Q2 		$135M Sell
2,007,464
-338,113
-14% -$21.5M 0.01% 844
2022
Q1 		$193M Sell
2,345,577
-390,226
-14% -$39.9M 0.02% 791
2021
Q4 		$401M Buy
2,735,803
+85,542
+3% +$13.3M 0.03% 536
2021
Q3 		$469M Sell
2,650,261
-10,265
-0.4% -$1.65M 0.04% 446
2021
Q2 		$430M Sell
2,660,526
-122,998
-4% -$19.7M 0.03% 489
2021
Q1 		$477M Buy
2,783,524
+5,166
+0.2% +$1.02M 0.04% 445
2020
Q4 		$610M Buy
2,778,358
+292,756
+12% +$63.3M 0.05% 343
2020
Q3 		$413M Buy
2,485,602
+415,077
+20% +$56.8M 0.04% 381
2020
Q2 		$236M Sell
2,070,525
-702,188
-25% -$68.1M 0.03% 552
2020
Q1 		$213M Buy
2,772,713
+756,892
+38% +$67.9M 0.03% 490
2019
Q4 		$260M Sell
2,015,821
-173,652
-8% -$16.7M 0.03% 551
2019
Q3 		$171M Sell
2,189,473
-739,458
-25% -$69.4M 0.02% 680
2019
Q2 		$302M Sell
2,928,931
-1,677,339
-36% -$131M 0.04% 489
2019
Q1 		$338M Buy
4,606,270
+2,409,882
+110% +$164M 0.04% 439
2018
Q4 		$93.2M Buy
2,196,388
+63,699
+3% +$2.54M 0.01% 884
2018
Q3 		$100M Buy
2,132,689
+146,374
+7% +$8.15M 0.01% 947
2018
Q2 		$97.9M Buy
1,986,315
+800,223
+67% +$30.2M 0.01% 963
2018
Q1 		$36.4M Buy
+1,186,092
New +$32.9M ﹤0.01% 1442
2016
Q3 		– Sell
-1,593,092
Closed -$8.7M – 2707
2016
Q2 		$8.7M Sell
1,593,092
-1,018,537
-39% -$16.2M ﹤0.01% 2028
2016
Q1 		$55.9M Sell
2,611,629
-278,259
-10% -$6.22M 0.01% 1201
2015
Q4 		$91.3M Buy
2,889,888
+100,200
+4% +$3.54M 0.01% 1004
2015
Q3 		$96M Buy
2,789,688
+365,613
+15% +$11.1M 0.01% 969
2015
Q2 		$76.3M Hold
2,424,075
– – 0.01% 1147
2015
Q1 		$71.1M Buy
2,424,075
+1,112,452
+85% +$26.1M 0.01% 1188
2014
Q4 		$24.3M Buy
1,311,623
+67,348
+5% +$1.14M ﹤0.01% 1654
2014
Q3 		$21.8M Buy
1,244,275
+30,000
+2% +$560K ﹤0.01% 1698
2014
Q2 		$24.3M Sell
1,214,275
-219,986
-15% -$4.25M ﹤0.01% 1703
2014
Q1 		$27.4M Buy
1,434,261
+702,986
+96% +$14.6M ﹤0.01% 1617
2013
Q4 		$12.2M Buy
+731,275
New +$12.5M ﹤0.01% 1905

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Fidelity Investments's MRTX Position: Q1 2024 in Review

Fidelity Investments sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 4,240 shares — an estimated $249K sold.

Fidelity Investments first reported a position in MRTX in Q4 2013 and held it in 35 quarters. The position peaked at $610M in Q4 2020. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Fidelity Investments reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Fidelity Investments sold 4,240 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $249K.
  • Fidelity Investments first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2013 and held it in 35 quarters.
  • Fidelity Investments's Mirati Therapeutics, Inc. Common Stock position peaked at $610M in Q4 2020.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Fidelity Investments's 13F filing for Q1 2024, filed 13 May 2024.